DDInter336 DDInter1355
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin. Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer.[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer. Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin&reg;.
Celecoxib {u} (Compound) binds {v} (Gene) CA4
CA4 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Celecoxib {u} (Compound) resembles {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Oxaliplatin
Celecoxib {u} (Compound) binds {v} (Gene) CA4
CA4 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Oxaliplatin
Celecoxib {u} (Compound) resembles {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Vemurafenib {u} may lead to a major life threatening interaction when taken with {v} Oxaliplatin
Celecoxib {u} (Compound) resembles {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Celecoxib {u} (Compound) binds {v} (Gene) CA14
CA14 {u} (Gene) is bound by {v} (Compound) Zoledronic acid
Zoledronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Celecoxib {u} (Compound) resembles {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Celecoxib {u} (Compound) resembles {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Celecoxib {u} (Compound) binds {v} (Gene) CA12
CA12 {u} (Gene) is bound by {v} (Compound) Imatinib
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Celecoxib {u} (Compound) binds {v} (Gene) MAPK14
MAPK14 {u} (Gene) interacts with {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Celecoxib (Compound) binds CA4 (Gene) and CA4 (Gene) is bound by Oxaliplatin (Compound)
Celecoxib (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Oxaliplatin
Celecoxib (Compound) binds CA4 (Gene) and CA4 (Gene) is bound by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Oxaliplatin
Celecoxib (Compound) resembles Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound) and Vemurafenib may lead to a major life threatening interaction when taken with Oxaliplatin
Celecoxib (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Dapsone (Compound) and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Celecoxib (Compound) binds CA14 (Gene) and CA14 (Gene) is bound by Zoledronic acid (Compound) and Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Celecoxib (Compound) resembles Etoricoxib (Compound) and Etoricoxib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Oxaliplatin (Compound)
Celecoxib (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Celecoxib (Compound) binds CA12 (Gene) and CA12 (Gene) is bound by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Celecoxib (Compound) binds MAPK14 (Gene) and MAPK14 (Gene) interacts with GSTP1 (Gene) and GSTP1 (Gene) is bound by Oxaliplatin (Compound)